The American Journal of Medicine
Volume 123, Issue 7 , Pages 593-595, July 2010

Office Management after Myocardial Infarction

  • Wilbert S. Aronow, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Wilbert S. Aronow, MD, FACC, FAHA, Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595

Department of Medicine, Divisions of Cardiology, Geriatrics, and Pulmonary/Critical Care, New York Medical College, Valhalla, New York

Abstract 

Patients should have their modifiable coronary artery risk factors intensively treated after myocardial infarction. Hypertension should be treated with beta-blockers and angiotensin-converting enzyme inhibitors. The blood pressure should be reduced to less than 140/90 mm Hg or to less than 130/80 mm Hg in patients with diabetes or chronic kidney disease. The serum low-density lipoprotein cholesterol should be reduced to less than 70 mg/dL with statins if necessary. Diabetic patients should have their hemoglobin A1c reduced to less than 7.0%. Aspirin or clopidogrel, beta-blockers, and angiotensin-converting enzyme inhibitors should be given indefinitely unless contraindications exist to their use. Long-acting nitrates are effective anti-anginal and anti-ischemic drugs. After an infarction, patients at very high risk for sudden cardiac death should receive an implantable cardioverter-defibrillator. The 2 indications for coronary revascularization are prolongation of life and relief of unacceptable symptoms despite optimal medical management.

Keywords: Angiotensin-converting enzyme inhibitor, Beta-blocker, Coronary risk factors, Myocardial infarction, Statins

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: None.

 Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(10)00286-X

doi:10.1016/j.amjmed.2010.02.011

The American Journal of Medicine
Volume 123, Issue 7 , Pages 593-595, July 2010